Emilie Gardette

Part of Geosoft the Co. Ltd., GreenTech, Inc. is a wood furniture store. The private company is based in South Strafford, VT. GreenTech was acquired by Geosoft the Co. Ltd. on March 27, 1996.

Greentech SA manufactures and sells organic health and personal care products. It offers cosmetics, pharmaceutical drugs, and food supplements. The company was founded by Jean-Yves Berthon in 1992 and is headquartered in Saint-Beauzire, France.

Voxan-SCCM SA designs, manufactures, and markets touring motorcycles. Its product brands include Roadster, Cafe Racer, Scrambler, Street Scrambler, Black Magic, and Charade Racing. The company was founded in October 2002 and is headquartered in Issoire, France.

Biovitis SARL engages in the provision of viticultural techniques and wine production consulting services. It assists in vineyard restructuring, zoning, plant protection, and application of anti-parasite and weeding products. The company was founded in 1997 and is headquartered in Andernos, France.

Emeraude SAS provides general construction services. It offers energy renovation, facade treatment, cladding, thermal insulation, waterproofing, decoration and stone treatment services. The company was founded by Kamel Bouslama in 1995 and is headquartered in Tremblay-en-France, France.

Part of Société Générale SA, Camilla SNC is an investment holding French company. The private company is based in Puteaux, France and was founded in 2005.

Baste SA wholesales bread, cakes and pastries. The company was founded in 1971 and is headquartered in Stosswihr, France.

Indicia Production SASU provides biotechnology research and development services. It manufactures ready-to-use microbiological media for the food and pharmaceutical industry. The company was founded in 1993 and is headquartered in Saint-Genis-l'Argentiere, France.

Based in Lyon within the Center of excellence in Infectious Diseases, Platine Pharma Services is an essential source of immune information for scientists and clinicians. From protocol support to regulatory reports, the company designs, performs and interprets complex molecular and cellular assays. Platine actively supports the development of in-vitro diagnostic, cosmetic and therapeutic product candidates, highlighting key markers and features in both normal and pathological conditions, and guiding decisions at each development stage. Using state-of-the-art technologies such as multi-parametric flow cytometry, Singulex, Luminex, Mesoscale Discovery, ELISpot or ELISA, Platine Pharma Services offers a fit-for-purpose approach to its customers and partners.

BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon.

Transcure Bioservices SAS provides research and development platforms service. It offer services to pharmaceutical, biotech, start-up, and academic researchers who need solutions for drug profiling and development. The company was founded on June 07, 2012 and is headquartered in Archamps, France.

Greensea SAS provides sea aquaculture services. The private company is based in Saint-Beauzire, France.

MabDesign Association is a French biotherapy industry association that aims to structure the biopharmaceutical industry from its R&D phases to biomanufacturing and marketing. The private company is based in Lyon, France and was founded in 2014. The association offers services to help companies strengthen their competitiveness and implement a solid intellectual property strategy. MabDesign's board of directors is composed of a pharmaceutical industry college and a competitiveness cluster college. The CEO is Nicolas Groux.

Altinat SAS provides business and management advisory services. The private company is based in Saint-Beauzire, France. The French company was founded in 2003. Veronique Berthon has been the CEO of the company since 2018.

SCI NOREL is a French company that leases land and other real estate properties. The private company is based in Saint-Georges-sur-Baulche, France.

Indicia Participations functions as an investment holding French company. The private company is based in Saint-Genis-l'Argentière, France.

SCI CALIFORNIE is a French company that leases real estate properties.

Mexbrain SAS is a French company that specializes in increasing the efficiency of treatment by combining the best of both worlds. The company is based in Fontaines-Saint-Martin, France. Mexbrain invites interested parties to contact them for any questions or investment opportunities. However, Thomas Brichart has been the CEO since incorporation.

Brenus Pharma SAS is a French company that has developed an allogeneic platform to generate first in class immune therapy to prevent cancer resistance over treatment. The company is based in Issoire, France. The company's technology, stc10-10, targets mss and msi-h population with a robust and validated preclinical data pack to offer an off-the-shelf technology allowing control of both time and cost of the manufacturing process. Brenus Pharma aims to harness a specific, highly potent, and durable immune response against moving targets in cancer by claiming the representativity, the antigenicity, and the immunogenicity of its solution. The company was founded by Benoit Pinteur, Jacques Gardette. The CEO is Paul Bravetti.

Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison.